Abstract:China initiated its healthcare reform in 2009 to provide accessible and affordable healthcare to all. We summarised China's drug reforms between 2009 and 2020 using the WHO framework. China has initiated comprehensive drug policies to address different issues, including: (1) issuing or amending major regulations with changes in institutional settings; (2) implementing the marketing authorisation holder system and bioequivalence assessment to improve the quality of drugs; (3) leveraging accelerated market approval and insurance listing to encourage needs-driven innovation and improve the access to new drugs; (4) introducing compulsory licensing to address major public health threats when needed; (5) scaling up the National Essential Medicine Policy and introducing pharmacoeconomic evaluation in National Reimbursable Drug List to promote rational use of medicine and evidence-based selection; (6) applying differentiated pricing strategies and scaling up zero mark-up policies to form a new financing mechanism; (7) adapting bulk procurement and placing strict regulations on the supply chain management to ensure supply and reduce the cost; (8) empowering pharmacists to improve the rational use of medicine; and (9) using procurement and supply chain digital platforms to inform decision and improve efficiency. China's drug reform has adopted a phased and systemic approach that mobilises multiple policy levers including governance, regulation and financing. Despite the progress, emerging challenges in implementation, coordination and capacity need to be addressed. Cross-cutting lessons from China's drug reforms include aligning the drug reform with the overall health reforms, adapting a systemic approach that mobilised policy levers and stakeholders and informing policy decision by conducting pilot studies.

International Experience in the Management of OTC Drugs' Reimbursement

Experiences on Reimbursement of Classified Drugs in Other Countries and Areas

Reform of the Essential Drugs Supply Mode in One District,shanghai

Experience and Enlightenment of Drug Price Regulation in Germany,Japan and Taiwan Area of China

International Experience of Pharmacoeconomic Evaluation in Health Decision-making

Drug pricing reform in China: analysis of piloted approaches and potential impact of the reform.

Comparative Study on the Policies of Drug Price and Expenditure Control in China and Other Countries

Specific Role of Pharmacoeconomics in the Medical Reform Program Implementation

A review on international experience of implementing dispensing fee

The Present and the Future: OTC Drug List in China

International Experiences of Medicines Insurance Payment Pricing Mechanisms and the Implications to China

International Comparison of Drug Price Level in China

Evaluation of Pharmaceutical Management Reform in Minhang District Shanghai City, China

International Experience of Utilizing Pharmacoeconomic Evidences and the Application in China

Improving access to medicines: lessons from 10 years of drug reforms in China, 2009-2020

Recent Pricing Negotiations on Innovative Medicines Pilot in China: Experiences, Implications, and Suggestions

Issues in Drug Pricing,Reimbursement and Access in China from the International Perspectives

Progress on Drug Pricing Negotiations in China.

Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts

Effects and problems in the global budget management of health insurance in Shanghai

A comparative study of the drug negotiation mechanism in typical regions at home and abroad